Stock market data and financial news reports

Eli Lilly's Zepbound Promising in Phase 3 Sleep Apnea Trials, FDA Submission Planned

Apr 17, 2024, 03:30 PM

Eli Lilly's weight-loss drug, Zepbound, has shown significant promise in treating obstructive sleep apnea, according to results from Phase 3 clinical trials. The drug, which costs about $1,000 a month and is already popular for weight loss, helped reduce episodes of irregular breathing in patients with the sleep-related disorder. This development could make Zepbound the first pharmaceutical treatment specifically approved for obstructive sleep apnea. Eli Lilly plans to submit these findings to the FDA, aiming for an expanded use approval. The company also highlighted that the drug reduced sleep apnea severity by nearly two-thirds in adults.